amikacin has been researched along with Atherogenesis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Duan, Y; Han, J; Li, Q; Li, X; Li, Y; Liu, L; Liu, Y; Ma, C; Miao, QR; Sun, L; Yang, X; Yu, M; Zeng, P; Zhang, R; Zhu, Y | 1 |
1 other study(ies) available for amikacin and Atherogenesis
| Article | Year |
|---|---|
Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Topics: AMP-Activated Protein Kinases; Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Biomarkers; Cholesterol, LDL; Disease Models, Animal; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Hep G2 Cells; Humans; Hypolipidemic Agents; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Oligopeptides; Phenotype; Piperidines; Plaque, Atherosclerotic; PPAR gamma; Proprotein Convertase 9; Receptors, Adiponectin; Receptors, LDL; Response Elements; RNA Interference; Signal Transduction; Sterol Regulatory Element Binding Protein 2; Transcriptional Activation; Transfection; Up-Regulation | 2017 |